Thank you for your interest. Give here your contact details and you'll receive an email with the pdf file you request.
First results of the BIOCYCLE project will be presented during the ECCO’17 Congress in Barcelona on February 15th, 2017
This project, funded by the European commission under the Horizon 2020 program, aims at exploring different aspects of the question of treatment de-escalation in moderate-severe Crohn’s disease (CD), first requiring a combination therapy with anti-TNF and antimetabolites to control the disease. The global aim of BIOCYCLE is to try and bring an integrated multidimensional and tailored response to this difficult question of treatment de-escalation in Crohn’s disease, also taking into account patients’ preferences and perspectives.
A digital oral presentation will summarize the first results of the healthcare providers’ survey, performed in United States (US) (through CCFA channels) and in Europe (through ECCO). Indeed, when patients with CD are in remission on combination therapy including an anti-TNF agent and an anti-metabolite, a frequent question is if it is appropriate to stop one of these medications. The aim of this survey was to capture and understand gastroenterologists’ perspectives (expectations, fears, priorities) on stopping therapy for patients with CD who are in remission, and to identify differences between European and US providers.
The SPARE clinical trial has also fully started and multiple centres are currently recruiting. Over 70 patients have been recruited so far in about 30 centres. Overall the recruitment process should be prolonged all over 2017 and 300 patients are expected to be recruited in 70 centres.
EU reference: grant agreement No 633168 – BIOCYCLE (PHC-13-2014)
In collaboration with a team at the University of California at Los Angeles (UCLA), researchers from GIGA-Neurosciences have discovered a new gene responsible for a seizure syndrome called juvenile myoclonic epilepsy (JME). This discovery was made as part of an international consortium that studies genetic abnormalities responsible for epileptic diseases. It is being published this week in
The LIGHTSHEET MICROSCOPY can deliver optical sections, 3D reconstructions and timelapse movies of whole sample volumes at subcellular resolutions. The fast scan speeds and low phototoxicity of the lightsheet allow to record the development of fluorescent transgenic animals over long time periods, such as zebrafish embryos. Alternatively 3D reconstructions of fixed whole organs or whole embryos,
The researchers discovered that this cellular dialogue controls the growth of the cerebral cortex and that its impairment leads a cortical malformation previously associated with autism in mice . Their results are published in the prestigious scientific journal Cell. The cerebral cortex contains excitatory and inhibitory interneurons. The former are produced locally and move by